{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T14:43:53Z","timestamp":1783435433975,"version":"3.54.6"},"reference-count":93,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:00:00Z","timestamp":1739923200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016879","name":"Union Chimique Belge","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016879","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.ard.2025.02.009","type":"journal-article","created":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T16:42:09Z","timestamp":1744735329000},"page":"927-936","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Chasing the target: reports from the Advances in Targeted Therapies meeting, 2024"],"prefix":"10.1016","volume":"84","author":[{"given":"Kevin L.","family":"Winthrop","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Bathon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Kerschbaumer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Isaacs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Mease","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaque-Eric","family":"Gottenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary K.","family":"Crow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Kay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie","family":"Crofford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xenofon","family":"Baraliakos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian","family":"Bykerk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Siebert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margreet","family":"Kloppenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Aletaha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iain B.","family":"McInnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Huizinga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhard","family":"Voll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen M.","family":"Gravallese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferdinand C.","family":"Breedveld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"van Vollenhoven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josef S.","family":"Smolen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ard.2025.02.009_bib0001","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1136\/ard-2023-224916","article-title":"Unmet need in rheumatology: reports from the Advances in Targeted Therapies meeting, 2023","volume":"83","author":"Winthrop","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.ard.2025.02.009_bib0002","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/s41467-018-02892-y","article-title":"Functionally distinct disease-associated fibroblast subsets in rheumatoid arthritis","volume":"9","author":"Mizoguchi","year":"2018","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.ard.2025.02.009_bib0003","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s13075-024-03343-4","article-title":"Targeting pathogenic fibroblast-like synoviocyte subsets in rheumatoid arthritis","volume":"26","author":"Qian","year":"2024","journal-title":"Arthritis Res Ther"},{"issue":"9","key":"10.1016\/j.ard.2025.02.009_bib0004","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1016\/j.celrep.2019.07.091","article-title":"Molecular portraits of early rheumatoid arthritis identify clinical and treatment response phenotypes","volume":"28","author":"Lewis","year":"2019","journal-title":"Cell Rep"},{"issue":"20","key":"10.1016\/j.ard.2025.02.009_bib0005","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.160964","article-title":"Randomized phase I trial of antigen-specific tolerizing immunotherapy with peptide\/calcitriol liposomes in ACPA+ rheumatoid arthritis","volume":"7","author":"Sonigra","year":"2022","journal-title":"JCI Insight"},{"issue":"8","key":"10.1016\/j.ard.2025.02.009_bib0006","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1136\/annrheumdis-2016-210511","article-title":"How common is clinically inactive disease in a prospective cohort of patients with juvenile idiopathic arthritis? The importance of definition","volume":"76","author":"Shoop-Worrall","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.ard.2025.02.009_bib0007","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/s41584-020-0413-5","article-title":"Restoring synovial homeostasis in rheumatoid arthritis by targeting fibroblast-like synoviocytes","volume":"16","author":"Nygaard","year":"2020","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"10.1016\/j.ard.2025.02.009_bib0008","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/imr.12986","article-title":"Fibroblast pathology in inflammatory joint disease","volume":"302","author":"Marsh","year":"2021","journal-title":"Immunol Rev"},{"issue":"6","key":"10.1016\/j.ard.2025.02.009_bib0009","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/iji.12637","article-title":"Epigenome-wide methylation haplotype association analysis identified HLA-DRB1, HLA-DRB5 and HLA-DQB1 as risk factors for rheumatoid arthritis","volume":"50","author":"Xu","year":"2023","journal-title":"Int J Immunogenet"},{"issue":"11","key":"10.1016\/j.ard.2025.02.009_bib0010","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1136\/ard-2024-226017","article-title":"Clinical efficacy and autoantibody seroconversion with CD19-CAR T cell therapy in a patient with rheumatoid arthritis and coexisting myasthenia gravis","volume":"83","author":"Haghikia","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"7987","key":"10.1016\/j.ard.2025.02.009_bib0011","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/s41586-023-06708-y","article-title":"Deconstruction of rheumatoid arthritis synovium defines inflammatory subtypes","volume":"623","author":"Zhang","year":"2023","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.ard.2025.02.009_bib0012","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41584-023-01052-x","article-title":"Profiling joint tissues at single-cell resolution: advances and insights","volume":"20","author":"Pandey","year":"2024","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"10.1016\/j.ard.2025.02.009_bib0013","doi-asserted-by":"crossref","first-page":"8172","DOI":"10.1038\/s41467-023-44053-w","article-title":"The long non-coding RNA HOTAIR contributes to joint-specific gene expression in rheumatoid arthritis","volume":"14","author":"Elhai","year":"2023","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.ard.2025.02.009_bib0014","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1097\/BOR.0000000000000782","article-title":"Racial, ethnic, and healthcare disparities in rheumatoid arthritis","volume":"33","author":"Yip","year":"2021","journal-title":"Curr Opin Rheumatol"},{"issue":"1","key":"10.1016\/j.ard.2025.02.009_bib0015","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s41572-021-00293-y","article-title":"Psoriatic arthritis","volume":"7","author":"FitzGerald","year":"2021","journal-title":"Nat Rev Dis Primers"},{"issue":"6","key":"10.1016\/j.ard.2025.02.009_bib0016","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.semarthrit.2017.10.021","article-title":"Considerations for the definition of remission criteria in psoriatic arthritis","volume":"47","author":"Mease","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.ard.2025.02.009_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2023.152275","article-title":"Characteristics of difficult-to-treat psoriatic arthritis: a comparative analysis","volume":"63","author":"Philippoteaux","year":"2023","journal-title":"Semin Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.ard.2025.02.009_bib0018","doi-asserted-by":"crossref","first-page":"e716","DOI":"10.1016\/S2665-9913(23)00264-3","article-title":"Sex-related differences in patient characteristics, and efficacy and safety of advanced therapies in randomised clinical trials in psoriatic arthritis: a systematic literature review and meta-analysis","volume":"5","author":"Eder","year":"2023","journal-title":"Lancet Rheumatol"},{"issue":"1","key":"10.1016\/j.ard.2025.02.009_bib0019","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003809","article-title":"Difficult-to-treat psoriatic arthritis (D2T PsA): a scoping literature review informing a GRAPPA research project","volume":"10","author":"Singla","year":"2024","journal-title":"RMD Open"},{"issue":"3","key":"10.1016\/j.ard.2025.02.009_bib0020","doi-asserted-by":"crossref","first-page":"rkae074","DOI":"10.1093\/rap\/rkae074","article-title":"Deciphering difficult-to-treat psoriatic arthritis (D2T-PsA): a GRAPPA perspective from an international survey of healthcare professionals","volume":"8","author":"Ribeiro","year":"2024","journal-title":"Rheumatol Adv Pract"},{"issue":"3","key":"10.1016\/j.ard.2025.02.009_bib0021","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1136\/ard-2023-225087","article-title":"Time to address the challenge of difficult to treat psoriatic arthritis: results from an international survey","volume":"83","author":"Marzo-Ortega","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.ard.2025.02.009_bib0022","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/s41584-024-01083-y","article-title":"Difficult-to-treat psoriatic arthritis: moving out of the rheumatoid arthritis shadow","volume":"20","author":"Siebert","year":"2024","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"10.1016\/j.ard.2025.02.009_bib0023","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1136\/annrheumdis-2020-217344","article-title":"EULAR definition of difficult-to-treat rheumatoid arthritis","volume":"80","author":"Nagy","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.02.009_bib0024","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1283251","article-title":"Dual targeted therapy in patients with psoriatic arthritis and spondyloarthritis: a real-world multicenter experience from Spain","volume":"14","author":"Valero-Mart\u00ednez","year":"2023","journal-title":"Front Immunol"},{"issue":"9","key":"10.1016\/j.ard.2025.02.009_bib0025","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1007\/s10067-023-06605-9","article-title":"Difficult to treat psoriatic arthritis - how should we manage?","volume":"42","author":"Kumthekar","year":"2023","journal-title":"Clin Rheumatol"},{"issue":"4","key":"10.1016\/j.ard.2025.02.009_bib0026","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S2468-1253(22)00427-7","article-title":"Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial","volume":"8","author":"Feagan","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.ard.2025.02.009_bib0027","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s11306-023-02079-7","article-title":"Classifying patients with psoriatic arthritis according to their disease activity status using serum metabolites and machine learning","volume":"20","author":"Koussiouris","year":"2024","journal-title":"Metabolomics"},{"issue":"Suppl 2","key":"10.1016\/j.ard.2025.02.009_bib0028","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3899\/jrheum.2023-0534","article-title":"Proceedings of the collaborative research network meeting at the GRAPPA 2022 annual meeting","volume":"50","author":"Ng","year":"2023","journal-title":"J Rheumatol"},{"issue":"8","key":"10.1016\/j.ard.2025.02.009_bib0029","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-cell therapy in autoimmune disease - a case series with follow-up","volume":"390","author":"M\u00fcller","year":"2024","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.ard.2025.02.009_bib0030","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1136\/annrheumdis-2019-215707","article-title":"Do patients with axial spondyloarthritis with radiographic sacroiliitis fulfil both the modified New York criteria and the ASAS axial spondyloarthritis criteria? Results from eight cohorts","volume":"78","author":"Boel","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.ard.2025.02.009_bib0031","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1002\/art.40866","article-title":"A fifty-two-week, randomized, placebo-controlled trial of certolizumab pegol in nonradiographic axial spondyloarthritis","volume":"71","author":"Deodhar","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.ard.2025.02.009_bib0032","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2017-211734","article-title":"Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force","volume":"77","author":"Smolen","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.ard.2025.02.009_bib0033","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1002\/acr.21688","article-title":"Do patients with non-radiographic axial spondylarthritis differ from patients with ankylosing spondylitis?","volume":"64","author":"Kiltz","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"5","key":"10.1016\/j.ard.2025.02.009_bib0034","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1136\/ard-2023-225185","article-title":"Goodbye to the term \u2018ankylosing spondylitis\u2019, hello \u2018axial spondyloarthritis\u2019: time to embrace the ASAS-defined nomenclature","volume":"83","author":"van der Heijde","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.ard.2025.02.009_bib0035","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.1002\/art.38140","article-title":"Tumor necrosis factor \u03b1 inhibition in radiographic and nonradiographic axial spondyloarthritis: results from a large observational cohort","volume":"65","author":"Ciurea","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.ard.2025.02.009_bib0036","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1136\/annrheumdis-2013-204055","article-title":"Evolution of radiographic damage in ankylosing spondylitis: a 12 year prospective follow-up of the OASIS study","volume":"74","author":"Ramiro","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.ard.2025.02.009_bib0037","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s40261-020-00886-7","article-title":"Comparison of the effects of secukinumab and adalimumab biosimilar on radiographic progression in patients with ankylosing spondylitis: design of a randomized, phase IIIb study (SURPASS)","volume":"40","author":"Baraliakos","year":"2020","journal-title":"Clin Drug Investig"},{"issue":"1","key":"10.1016\/j.ard.2025.02.009_bib0038","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1093\/rheumatology\/kew367","article-title":"Efficiency of treatment with non-steroidal anti-inflammatory drugs according to current recommendations in patients with radiographic and non-radiographic axial spondyloarthritis","volume":"56","author":"Baraliakos","year":"2017","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.ard.2025.02.009_bib0039","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41584-019-0341-4","article-title":"Do NSAIDs affect radiographic progression in axial SpA?","volume":"16","author":"Braun","year":"2020","journal-title":"Nat Rev Rheumatol"},{"issue":"10","key":"10.1016\/j.ard.2025.02.009_bib0040","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1136\/annrheumdis-2012-201370","article-title":"Continuous NSAID use reverts the effects of inflammation on radiographic progression in patients with ankylosing spondylitis","volume":"71","author":"Kroon","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.ard.2025.02.009_bib0041","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1136\/ard-2023-224699","volume":"83","author":"Proft","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.ard.2025.02.009_bib0042","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1038\/s41598-019-57215-y","article-title":"Chronotherapy of non-steroidal anti-inflammatory drugs may enhance postoperative recovery","volume":"10","author":"Al-Waeli","year":"2020","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.ard.2025.02.009_bib0043","first-page":"125","article-title":"Radiological scoring methods in ankylosing spondylitis. Reliability and change over 1 and 2 years","volume":"31","author":"Spoorenberg","year":"2004","journal-title":"J Rheumatol"},{"issue":"2","key":"10.1016\/j.ard.2025.02.009_bib0044","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1136\/annrheumdis-2017-211989","article-title":"Low-dose CT detects more progression of bone formation in comparison to conventional radiography in patients with ankylosing spondylitis: results from the SIAS cohort","volume":"77","author":"de Koning","year":"2018","journal-title":"Ann Rheum Dis. Feb"},{"issue":"1","key":"10.1016\/j.ard.2025.02.009_bib0045","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-004009","article-title":"Association of nociplastic and neuropathic pain components with the presence of residual symptoms in patients with axial spondyloarthritis receiving biological disease-modifying antirheumatic drugs","volume":"10","author":"Al Mohamad","year":"2024","journal-title":"RMD Open"},{"issue":"9","key":"10.1016\/j.ard.2025.02.009_bib0046","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1136\/ard.2007.082529","article-title":"Adalimumab effectively reduces the signs and symptoms of active ankylosing spondylitis in patients with total spinal ankylosis","volume":"67","author":"van der Heijde","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.ard.2025.02.009_bib0047","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/j.joca.2010.07.011","article-title":"Treatment with TNF-alpha inhibitor infliximab might reduce hand osteoarthritis in patients with rheumatoid arthritis","volume":"18","author":"G\u00fcler-Y\u00fcksel","year":"2010","journal-title":"Osteoarthritis Cartilage"},{"issue":"1","key":"10.1016\/j.ard.2025.02.009_bib0048","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002837","article-title":"Comparison of patients with axial PsA and patients with axSpA and concomitant psoriasis: an analysis of the German register RABBIT-SpA","volume":"9","author":"Regierer","year":"2023","journal-title":"RMD Open"},{"issue":"1","key":"10.1016\/j.ard.2025.02.009_bib0049","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1093\/rheumatology\/kead162","article-title":"Magnetic resonance imaging characteristics in patients with psoriatic arthritis and axial manifestations from the MAXIMISE cohort","volume":"63","author":"Baraliakos","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ard.2025.02.009_bib0050","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X211057975","article-title":"Axial involvement in psoriatic arthritis cohort (AXIS): the protocol of a joint project of the Assessment of SpondyloArthritis International Society (ASAS) and the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)","volume":"13","author":"Poddubnyy","year":"2021","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"9","key":"10.1016\/j.ard.2025.02.009_bib0051","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.1093\/rheumatology\/kead022","article-title":"ROR\u03b3t inhibition ameliorates IL-23 driven experimental psoriatic arthritis by predominantly modulating \u03b3\u03b4-T cells","volume":"62","author":"Mortier","year":"2023","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1016\/j.ard.2025.02.009_bib0052","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1136\/annrheumdis-2017-212603","article-title":"Stratification of knee osteoarthritis: two major patient subgroups identified by genome-wide expression analysis of articular cartilage","volume":"77","author":"Soul","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.ard.2025.02.009_bib0053","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1038\/s41591-020-1013-2","article-title":"Articular cartilage regeneration by activated skeletal stem cells","volume":"26","author":"Murphy","year":"2020","journal-title":"Nat Med"},{"issue":"8","key":"10.1016\/j.ard.2025.02.009_bib0054","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1136\/annrheumdis-2020-219181","article-title":"Long-term structural and symptomatic effects of intra-articular sprifermin in patients with knee osteoarthritis: 5-year results from the FORWARD study","volume":"80","author":"Eckstein","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"14","key":"10.1016\/j.ard.2025.02.009_bib0055","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1001\/jama.2019.14735","article-title":"Effect of intra-articular sprifermin vs placebo on femorotibial joint cartilage thickness in patients with osteoarthritis: the FORWARD randomized clinical trial","volume":"322","author":"Hochberg","year":"2019","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.ard.2025.02.009_bib0056","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1136\/ard.2010.142364","article-title":"Tissue structure modification in knee osteoarthritis by use of joint distraction: an open 1-year pilot study","volume":"70","author":"Intema","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.ard.2025.02.009_bib0057","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1093\/rheumatology\/keab456","article-title":"Knee joint distraction results in MRI cartilage thickness increase up to 10 years after treatment","volume":"61","author":"Jansen","year":"2022","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"10.1016\/j.ard.2025.02.009_bib0058","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1016\/j.joca.2013.08.006","article-title":"Sustained clinical and structural benefit after joint distraction in the treatment of severe knee osteoarthritis","volume":"21","author":"Wiegant","year":"2013","journal-title":"Osteoarthritis Cartilage"},{"issue":"12","key":"10.1016\/j.ard.2025.02.009_bib0059","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1038\/s41591-022-02059-9","article-title":"Angiopoietin-like 3-derivative LNA043 for cartilage regeneration in osteoarthritis: a randomized phase 1 trial","volume":"28","author":"Gerwin","year":"2022","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.ard.2025.02.009_bib0060","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.joca.2019.12.005","article-title":"The molecular profile of synovial fluid changes upon joint distraction and is associated with clinical response in knee osteoarthritis","volume":"28","author":"Watt","year":"2020","journal-title":"Osteoarthritis Cartilage"},{"issue":"9","key":"10.1016\/j.ard.2025.02.009_bib0061","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1136\/ard-2023-223845","article-title":"Glucagon-like peptide-1 receptor agonists as a disease-modifying therapy for knee osteoarthritis mediated by weight loss: findings from the Shanghai osteoarthritis cohort","volume":"82","author":"Zhu","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.02.009_bib0062","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.bcp.2019.03.030","article-title":"Adipokines: linking metabolic syndrome, the immune system, and arthritic diseases","volume":"165","author":"Francisco","year":"2019","journal-title":"Biochem Pharmacol"},{"issue":"4","key":"10.1016\/j.ard.2025.02.009_bib0063","doi-asserted-by":"crossref","first-page":"R126","DOI":"10.1186\/ar3064","article-title":"Exercise increases interleukin-10 levels both intraarticularly and peri-synovially in patients with knee osteoarthritis: a randomized controlled trial","volume":"12","author":"Helmark","year":"2010","journal-title":"Arthritis Res Ther"},{"issue":"11","key":"10.1016\/j.ard.2025.02.009_bib0064","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1016\/j.joca.2019.07.012","article-title":"The nociceptive innervation of the normal and osteoarthritic mouse knee","volume":"27","author":"Obeidat","year":"2019","journal-title":"Osteoarthritis Cartilage"},{"issue":"9","key":"10.1016\/j.ard.2025.02.009_bib0065","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.joca.2020.05.010","article-title":"Contribution of nerves within osteochondral channels to osteoarthritis knee pain in humans and rats","volume":"28","author":"Aso","year":"2020","journal-title":"Osteoarthritis Cartilage"},{"issue":"4","key":"10.1016\/j.ard.2025.02.009_bib0066","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.jegh.2015.04.006","article-title":"Role of patient-reported outcomes and other efficacy endpoints in the drug approval process in Europe (2008-2012)","volume":"5","author":"Bansal","year":"2015","journal-title":"J Epidemiol Glob Health"},{"key":"10.1016\/j.ard.2025.02.009_bib0067","unstructured":"Diseases in Need of Research and Advocacy (DINORA). Pre-Competitive Consortium for Osteoarthritis Clinical Trial Outcomes Improvement (PROACTIVE) [Internet]; 2024 [cited 2024 Apr 12]. Available from: https:\/\/www.dinora.com\/proactive.html."},{"issue":"6","key":"10.1016\/j.ard.2025.02.009_bib0068","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMc2107725","article-title":"CD19-targeted CAR T cells in refractory systemic lupus erythematosus","volume":"385","author":"Mougiakakos","year":"2021","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.ard.2025.02.009_bib0069","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.ard.2025.02.009_bib0070","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jtct.2022.10.004","article-title":"Successful generation of CD19 chimeric antigen receptor T cells from patients with advanced systemic lupus erythematosus","volume":"29","author":"Kretschmann","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"10437","key":"10.1016\/j.ard.2025.02.009_bib0071","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/S0140-6736(24)00424-0","article-title":"CAR T-cell therapy rescues adolescent with rapidly progressive lupus nephritis from haemodialysis","volume":"403","author":"Krickau","year":"2024","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.ard.2025.02.009_bib0072","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1136\/ard-2024-225785","article-title":"BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial","volume":"83","author":"Wang","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.ard.2025.02.009_bib0073","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1097\/MOH.0000000000000531","article-title":"Application of stem cell transplantation in autoimmune diseases","volume":"26","author":"Ng","year":"2019","journal-title":"Curr Opin Hematol"},{"issue":"6","key":"10.1016\/j.ard.2025.02.009_bib0074","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/s41409-018-0173-x","article-title":"Five year follow-up after autologous peripheral blood hematopoietic stem cell transplantation for refractory, chronic, corticosteroid-dependent systemic lupus erythematosus: effect of conditioning regimen on outcome","volume":"53","author":"Burt","year":"2018","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.ard.2025.02.009_bib0075","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2022-000704","article-title":"Safety, immunological effects and clinical response in a phase I trial of umbilical cord mesenchymal stromal cells in patients with treatment refractory SLE","volume":"9","author":"Kamen","year":"2022","journal-title":"Lupus Sci Med"},{"issue":"6","key":"10.1016\/j.ard.2025.02.009_bib0076","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s10875-007-9120-0","article-title":"Resetting the adaptive immune system after autologous stem cell transplantation: lessons from responses to vaccines","volume":"27","author":"Brinkman","year":"2007","journal-title":"J Clin Immunol"},{"issue":"1","key":"10.1016\/j.ard.2025.02.009_bib0077","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1182\/blood-2008-07-168286","article-title":"Depletion of autoreactive immunologic memory followed by autologous hematopoietic stem cell transplantation in patients with refractory SLE induces long-term remission through de novo generation of a juvenile and tolerant immune system","volume":"113","author":"Alexander","year":"2009","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.ard.2025.02.009_bib0078","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1002\/eji.202049064","article-title":"CAR T cells: building on the CD19 paradigm","volume":"51","author":"Globerson Levin","year":"2021","journal-title":"Eur J Immunol"},{"issue":"3","key":"10.1016\/j.ard.2025.02.009_bib0079","article-title":"Co-stimulation of CD28\/CD40 signaling molecule potentiates CAR-T cell efficacy and stemness","volume":"32","author":"Khopanlert","year":"2024","journal-title":"Mol Ther Oncol"},{"issue":"10","key":"10.1016\/j.ard.2025.02.009_bib0080","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/s41584-020-0480-7","article-title":"New insights into the role of antinuclear antibodies in systemic lupus erythematosus","volume":"16","author":"Pisetsky","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.ard.2025.02.009_bib0081","doi-asserted-by":"crossref","DOI":"10.1016\/j.coph.2022.102291","article-title":"Advances in lupus therapeutics: achieving sustained control of the type I interferon pathway","volume":"67","author":"Crow","year":"2022","journal-title":"Curr Opin Pharmacol"},{"issue":"1","key":"10.1016\/j.ard.2025.02.009_bib0082","article-title":"Therapeutic targeting of follicular T cells with chimeric antigen receptor-expressing natural killer cells","volume":"1","author":"Reighard","year":"2020","journal-title":"Cell Rep Med"},{"issue":"6","key":"10.1016\/j.ard.2025.02.009_bib0083","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.32604\/or.2024.049792","article-title":"Preclinical evaluation of cyclophosphamide and fludarabine combined with CD19 CAR-T in the treatment of B-cell hematologic malignancies in vivo","volume":"32","author":"Xia","year":"2024","journal-title":"Oncol Res"},{"issue":"9","key":"10.1016\/j.ard.2025.02.009_bib0084","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.bbmt.2010.03.014","article-title":"Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20\/CD19-specific chimeric antigen receptor redirected T cells in humans","volume":"16","author":"Jensen","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"10.1016\/j.ard.2025.02.009_bib0085","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S1474-4422(24)00140-6","article-title":"B cell-targeting chimeric antigen receptor T cells as an emerging therapy in neuroimmunological diseases","volume":"23","author":"Haghikia","year":"2024","journal-title":"Lancet Neurol"},{"issue":"6","key":"10.1016\/j.ard.2025.02.009_bib0086","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1136\/ard-2024-225638","article-title":"Potential and pitfalls of repurposing the CAR-T cell regimen for the treatment of autoimmune disease","volume":"83","author":"Daamen","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.ard.2025.02.009_bib0087","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41584-024-01139-z","article-title":"Advancements and challenges in CAR T cell therapy in autoimmune diseases","volume":"20","author":"Schett","year":"2024","journal-title":"Nat Rev Rheumatol"},{"issue":"2","key":"10.1016\/j.ard.2025.02.009_bib0088","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2022-000890","article-title":"Improving resource utilisation in SLE drug development through innovative trial design","volume":"10","author":"Garces","year":"2023","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.ard.2025.02.009_bib0089","doi-asserted-by":"crossref","first-page":"e52768","DOI":"10.2196\/52768","article-title":"Exploring the perspectives of patients living with lupus: retrospective social listening study","volume":"8","author":"Spies","year":"2024","journal-title":"JMIR Form Res"},{"issue":"4","key":"10.1016\/j.ard.2025.02.009_bib0090","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1007\/s10067-024-06909-4","article-title":"Evaluation of type 2 SLE symptoms in patients with a range of lupus nephritis activity","volume":"43","author":"Rogers","year":"2024","journal-title":"Clin Rheumatol"},{"issue":"1","key":"10.1016\/j.ard.2025.02.009_bib0091","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2022-000861","article-title":"Molecular endotypes of type 1 and type 2 SLE","volume":"10","author":"Robl","year":"2023","journal-title":"Lupus Sci Med"},{"issue":"10","key":"10.1016\/j.ard.2025.02.009_bib0092","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1002\/acr.25104","article-title":"Identifying and managing nociplastic pain in individuals with rheumatic diseases: a narrative review","volume":"75","author":"Murphy","year":"2023","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"3","key":"10.1016\/j.ard.2025.02.009_bib0093","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1093\/rheumatology\/keab501","article-title":"Serological abnormalities that predict progression to systemic autoimmune rheumatic diseases in antinuclear antibody-positive individuals","volume":"61","author":"Mu\u00f1oz-Grajales","year":"2022","journal-title":"Rheumatology (Oxford)"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496725002377?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496725002377?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T05:12:16Z","timestamp":1774415536000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496725002377"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":93,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S0003496725002377"],"URL":"https:\/\/doi.org\/10.1016\/j.ard.2025.02.009","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chasing the target: reports from the Advances in Targeted Therapies meeting, 2024","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ard.2025.02.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of European Alliance of Associations for Rheumatology (EULAR).","name":"copyright","label":"Copyright"}]}}